In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Into 2019: Digital Leads US Policy Innovations, But Public Medtech Scrutiny Grows

Executive Summary

Scott Gottlieb's FDA continues to push out policy reforms and experiments at a rapid pace, with special focus on digital and AI technologies. In parallel, US Medicare officials are more publicly signaling plans to roll out policies for a quicker path to reimbursement for new devices. However, public scrutiny of whether device regulations properly protect patient safety is growing, and it could have an impact. 

You may also be interested in...



Opinion: The Great Implant Scandal Or 7.7 Billion Reasons To Celebrate Medical Devices?

Investigative journalists, tort lawyers, the judicial system and public opinion all provide checks and balances on medical research, industrial innovation and commercial exploitation of health-care technologies. Whether those affected like it or not, these well-intentioned elements of society demand accountability of an industry that has a profound effect on all our lives. The "Implant Files" episode is a reminder for medtech stakeholders across the world that nothing can be taken for granted, says medtech industry and regulatory consultant Trevor Lewis in this guest column for Medtech Insight.

The Implant Files: EU Blamed For Regulatory Inadequacies The World Over While 'Wrath'-Behrendt Fumes

All over the world, the medtech industry woke up Monday morning to read highly critical reports of the way the medtech industry is regulated. Investigative pieces accuse the medtech industry of putting profits before safety, of sabotaging the EU's best efforts toward more appropriate regulation, and treating patients as guinea pigs. This is a first look at the International Consortium of Investigative Journalists' Implant Files investigation from an EU perspective. 

Jeff Shuren Talks Breakthrough Bonanza, TPLC And Innovating Safety

In an interview at The MedTech Conference in Philadelphia this week, US FDA device-center Director Jeff Shuren spoke to Medtech Insight about what is happening with the pending total product lifecycle office and the larger-than-expected response to the Breakthrough Devices Program. He also makes the point that supporting innovation and protecting safety are not opposing goals, and more.

Related Content

Topics

UsernamePublicRestriction

Register

IV124183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel